Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Legend Biotech Receives FDA IND Clearance for LB2501, a CD19/CD20 In Vivo CAR-T Therapy

16 October 2026 · By · Wire by Fusion42

Published

16 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at oncodaily.com →

◆ Verified

Fusion42 · 16 October 2026 · Fusion42 review

Legend Biotech received FDA IND clearance for LB2501, an investigational in vivo CAR-T therapy targeting CD19 and CD20 for relapsed or refractory B-cell malignancies, enabling a planned U.S. Phase 1/2 study.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 15 Oct 2026 and 16 Oct 2026.

◆ ◆ The Wire takeaway

You can now plan for the US trial opportunity as in vivo CAR-T therapy clears a key FDA milestone. Competition will rise in cell therapy delivery approaches that skip traditional manufacturing.

◆ Coverage

7 sources · first reported 15 Oct 2026 · latest 16 Oct 2026

◆ Topics

Biotechfda-indcar-tb-cell-malignanciesin-vivo-therapyclinical-trialdual-target